Skip to main content

Advertisement

SpringerLink
Log in

Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the 1-year effects of tadalafil on storage and voiding function in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (LUTS/BPH) based on a urodynamic study.

Methods

In a one-armed, prospective study, 105 untreated outpatients with LUTS/BPH received 5 mg tadalafil every day for 12 months. Subjective symptoms and objective findings on voiding and storage functions, obtained through urodynamic studies that included cystometry and pressure flow study, were evaluated before, at 3 months, and at 12 months of treatment.

Results

The analysis included 94 patients with a mean age of 70.7 years and a mean prostate volume of 44.5 mL. Subjective symptom parameters of LUTS were significantly ameliorated after 3 months, and progressively improved until study conclusion. Similarly, monitoring of storage and voiding functions revealed significant improvements after 3 months that continued to improve until 12 months. In 49 patients who revealed detrusor overactivity during cystometry at the baseline assessment, uninhibited detrusor contractions disappeared in 15 (30.6%) patients after 3 months (p = 0.02), and in 22 (44.9%) after 12 months (p < 0.001). Mean maximum flow rate significantly increased by 2.9 mL/s during the 12-month treatment (p < 0.001), whereas mean bladder outlet obstruction index significantly decreased from 59.5 at baseline to 45.7 at 3 months (p = 0.001), and to 42.9 at 12 months (p < 0.001).

Conclusions

Tadalafil significantly improved storage and voiding functions, along with LUTS, in patients with LUTS/BPH during a 1-year treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Homma Y, Gotoh M, Kawauchi A et al (2017) Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 24:716–729

    Article  PubMed  Google Scholar 

  2. Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099–1109

    Article  PubMed  Google Scholar 

  3. Gacci M, Andersson KE, Chapple C et al (2016) Latest Evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 70:124–133

    Article  CAS  PubMed  Google Scholar 

  4. Fusco F, Palmieri A, Ficarra V et al (2016) α1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 69:1091–1101

    Article  CAS  PubMed  Google Scholar 

  5. Oelke M, Shinghal R, Sontag A, Baygani SK, Donatucci CF (2015) Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol 193:1581–1589

    Article  CAS  PubMed  Google Scholar 

  6. Roehrborn CG, McVary KT, Elion-Mboussa A et al (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228–1234

    Article  CAS  PubMed  Google Scholar 

  7. Porst H, Kim ED, Casabé AR et al (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60:1105–1113

    Article  CAS  PubMed  Google Scholar 

  8. Bittencourt JA, Tano T, Gajar SA et al (2009) Relaxant effects of sildenafil on the human isolated bladder neck. Urology 73:427–430

    Article  PubMed  Google Scholar 

  9. Pinggera GM, Frauscher F, Paduch DA et al (2014) Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology 84:412–419

    Article  PubMed  Google Scholar 

  10. Kawai Y, Oka M, Yoshinaga R et al (2016) Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction. Neurourol Urodyn 35:444–449

    Article  CAS  PubMed  Google Scholar 

  11. Minagawa T, Aizawa N, Igawa Y et al (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 110:E259–E266

    Article  CAS  PubMed  Google Scholar 

  12. Vignozzi L, Gacci M, Cellai I et al (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 73:1391–1402

    Article  CAS  PubMed  Google Scholar 

  13. Morelli A, Comeglio P, Filippi S et al (2013) Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 73:428–441

    Article  CAS  PubMed  Google Scholar 

  14. Yokoyama O, Yoshida M, Kim SC et al (2013) Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol 20:193–201

    Article  CAS  PubMed  Google Scholar 

  15. Kim SC, Park JK, Kim SW et al (2011) Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Low Urin Tract Symptoms 3:86–93

    Article  CAS  PubMed  Google Scholar 

  16. Matsukawa Y, Majima T, Matsuo K et al (2018) Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a urodynamic-based study. Int J Urol 25:246–250

    Article  CAS  PubMed  Google Scholar 

  17. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  Google Scholar 

  18. Schäfer W, Abrams P, Liao L et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21:261–274

    Article  Google Scholar 

  19. Matsukawa Y, Gotoh M, Kato M et al (2014) Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study. Int J Urol 21:826–830

    Article  CAS  PubMed  Google Scholar 

  20. Matsukawa Y, Takai S, Funahashi Y et al (2016) The change of testosterone secretion during the treatment of alpha-1 blocker in patients with benign prostatic hyperplasia. Urology 88:149–154

    Article  PubMed  Google Scholar 

  21. Dmochowski R, Roehrborn C, Klise S et al (2010) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 183:1092–1097

    Article  CAS  PubMed  Google Scholar 

  22. Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925

    Article  CAS  PubMed  Google Scholar 

  23. Osman NI, Chapple CR, Abrams P et al (2014) Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 65:389–398

    Article  Google Scholar 

  24. Nomiya M, Burmeister DM, Sawada N et al (2013) Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol 189:754–761

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all patients for participating and all trial investigators for their contribution to data acquisition and patient care.

Funding

This study has supported by funding from Nippon Shinyaku Co., Ltd, Kyoto, Japan.

Author information

Authors and Affiliations

  1. Department of Urology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Yoshihisa Matsukawa, Shun Takai, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Masashi Kato, Tokunori Yamamoto & Momokazu Gotoh

Authors
  1. Yoshihisa Matsukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shun Takai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsuyoshi Majima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhito Funahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoto Sassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masashi Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tokunori Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Momokazu Gotoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YM: Protocol/project development, Data management, Manuscript writing/editing. ST: Data analysis. TM: Manuscript writing. YF: Data analysis. NS: Data management. MK: Protocol/project development. TY: Protocol/project development. MG: Protocol/project development, Manuscript editing.

Corresponding author

Correspondence to Yoshihisa Matsukawa.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The ethics committee of the Nagoya University Graduate School of Medicine approved this study protocol (IRB approval number: 2015-0106).

Informed consent

Informed consent was obtained from all individual participants included in the study before enrollment. The study was registered at https://center.umin.ac.jp as UMIN000017925.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsukawa, Y., Takai, S., Majima, T. et al. Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study. World J Urol 37, 867–872 (2019). https://doi.org/10.1007/s00345-018-2453-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-018-2453-x

Keywords

Search

Navigation